Assignee
CARTESIAN THERAPEUTICS INC
US·7 granted patents·9 pending applications·9 citations·filing 2017–2024
Top patents by PatentIndex Score
16 records- 0194US10934337B2Anti-BCMA chimeric antigen receptorsCARTESIAN THERAPEUTICS INC·Filed 2020·Granted Mar 2, 2021·8 cites·30 claims
- 0291US2025177360A1Methods related to administering immunosuppressants and therapeutic macromolecules at a reduced pharmacodynamically effective doseCARTESIAN THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0385US11220535B2Anti-BCMA chimeric antigen receptorsCARTESIAN THERAPEUTICS INC·Filed 2021·Granted Jan 11, 2022·1 cites·30 claims
- 0484US2025108094A1Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressantCARTESIAN THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0583US12472167B2Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both Type 1 and Type IV hypersensitivityCARTESIAN THERAPEUTICS INC·Filed 2022·Granted Nov 18, 2025·0 cites·20 claims
- 0681US2024294600A1Anti-bcma chimeric antigen receptorsCARTESIAN THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0780US12194078B2Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressantCARTESIAN THERAPEUTICS INC·Filed 2022·Granted Jan 14, 2025·0 cites·19 claims
- 0878US2025152561A1Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated stateCARTESIAN THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0976US12508249B2Methods related to administering immunosuppressants and non-allergenic antigens to reduce or prevent anaphylaxisCARTESIAN THERAPEUTICS INC·Filed 2020·Granted Dec 30, 2025·0 cites·23 claims
- 1075US11999773B2Anti-BCMA chimeric antigen receptorsCARTESIAN THERAPEUTICS INC·Filed 2021·Granted Jun 4, 2024·0 cites·10 claims
- 1175US2025057756A1Formulations and doses of pegylated uricaseCARTESIAN THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1275US2025090451A1Formulations and doses of pegylated uricaseCARTESIAN THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1361US2024344030A1Multiprotein-engineered cells secreting a multispecific antibodyCARTESIAN THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1454US12553041B2Formulations and doses of pegylated uricaseCARTESIAN THERAPEUTICS INC·Filed 2020·Granted Feb 17, 2026·0 cites·10 claims
- 1552US2023174944A1Engineered cells secreting therapeutic enzymesCARTESIAN THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1640US2019030073A1Cancer immunotherapy with highly enriched cd8+ chimeric antigen receptor t cellsCARTESIAN THERAPEUTICS INC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when CARTESIAN THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →